Bulletin: Update on Coronavirus 3/23

There was a lot of coronavirus news on Monday, March 23 – enough to justify a new update. Here are the latest developments related to the SARS-CoV-2 virus and the disease it causes, Covid-19.

Bulletin: Update on Coronavirus

Based on the latest data available as of 6 pm on March 22, 2020, this is the newest information about the SARS-CoV-2 virus and the disease it causes, Covid-19. The news is saturated with coronavirus news, so this bulletin is an attempt to highlight the key things you need to know from the last few days. It covers what\'s new in statistics, testing, treatments, vaccines, and more.

Bulletin: Update on Coronavirus

Based on the latest data available as of 9 am EDT on March 19, 2020, this is the newest information about the SARS-CoV-2 virus and the disease it causes, Covid-19. In particular, there is a look at the supply chain, infection protection, the drugs in development to treat Covid-19 that are getting the most attention right now, and current controversies.

Bulletin: Coronavirus Update

Here’s the latest news related to the SARS-CoV-2 virus and the disease it causes, Covid-19 – which has now been declared a pandemic. It’s a quick review of the extent of the problem, what government is doing, the impact on Americans, testing, treatments, vaccines, unanswered questions, and major medical conference schedule/changes.

COVID-19 Update from the Conference on Retroviruses and Opportunistic Infections (CROI)

A special virtual session on Covid-19 at CROI was one of the best briefings on this outbreak so far, with state of the outbreak reports from the chief epidemiologist of the China CDC, a U.S. CDC official, a noted virologist, and Dr. Anthony Fauci from the National Institute of Allergy and Infectious Diseases (NIAID). While the U.S. CDC seems stuck on \"Remember, there\'s plenty of soap,\" the other experts offered new, in-depth insights.

FDA Advisory Committee Rejects Nektar Therapeutics’ Opioid

Nektar Therapeutics thought it had a better, safer opioid, NKTR-181, a selective mu-opioid agonist that gets into the brain slower than other opioids. However, an FDA advisory committee voted unanimously to recommend against approval. The panel didn’t think the right patients were studied in the Phase III trial, didn’t think the safety data were sufficient, particularly the lack of an IV abuse study, and was worried that it would be over-used if approved and worsen the opioid epidemic. Bottom line: The panel just didn’t think another oral opioid was a good idea. As a result, Nektar is giving up on the drug.

American Society Of Plastic Surgeons (ASPS)

Breast implant volume is taking a hit from Allergan’s Biocell recall. Plastic surgeon procedure volume is steady, but without explants and replacements, it would be down. U.S. breast implants were already mostly smooth, but expanders are switching to textured to smooth as well. Europe has moved from 95% textured implants to 90% smooth implants. Allergan and Johnson & Johnson/ Mentor remain the leading breast implants, with competitors not gaining much traction. In a recession, doctors expect big-ticket procedures would decrease, with fillers and toxins the mainstay. There was little interest in threads, new fillers, or new uses for fillers at ASPS, but Evolus’ Jeuveau, a new toxin, got some attention, though it isn’t displacing Allergan’s Botox from its dominant toxin position. InMode’s laser workstations were generating some interest.

1 2 3 4 5 86